No Data
No Data
Buy Rating Affirmed for Gain Therapeutics Amidst Promising Clinical Trials and Strong Financial Health
Buy Rating Affirmed for Gain Therapeutics Amid Positive Clinical and Financial Performance
Gain Therapeutics | 10-Q: Quarterly report
Gain Therapeutics' Q1 Cash, Cash Equivalent And Marketable Securities Were $12.7M, With Cash Runway Guidance Into 2025
Gain Therapeutics' Q1 Cash, Cash Equivalent And Marketable Securities Were $12.7M, With Cash Runway Guidance Into 2025
Gain Therapeutics 1Q Loss/Shr 22c >GANX
Gain Therapeutics 1Q Loss/Shr 22c >GANX
Buy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical Progress